00:51 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Bleeding Patient sample and mouse studies suggest HIF1A stabilizers could help treat heavy menstrual bleeding. In endometrial samples from patients, levels of HIF1A were lower than in patients with normal menstrual bleeding. In a mouse...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

AKB-4924: Phase Ia started

Aerpio began a double-blind, placebo-controlled, Canadian Phase Ia trial to evaluate single doses of 20, 60, 120, 240, 360 and 480 mg oral AKB-4924 in up to 48 healthy male volunteers. Aerpio Therapeutics Inc., Cincinnati,...
07:00 , May 14, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Hypoxia-inducible factor 1α (HIF1A; HIF1-α)

Infectious disease INDICATION: Urinary tract infection (UTI) Cell culture and mouse studies suggest stabilizing HIF1A could help prevent or treat UTIs caused by uropathogenic Escherichia coli (UPEC). In UPEC-infected human uroepithelial cells, the HIF1A stabilizer AKB-4924 decreased...
07:00 , Apr 16, 2012 |  BioCentury  |  Emerging Company Profile

Aerpio: Stanching the leak

Anemia company Akebia Therapeutics Inc. spun out Aerpio Therapeutics Inc. in January to develop a Tie2 activator that not only could be more effective than VEGF inhibitors for diabetic macular edema, but also could treat...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

Akebia ophthalmic, autoimmune news

Akebia spun out Aerpio Therapeutics Inc. (Cincinnati, Ohio) to focus on diabetic eye disease. The newco's lead compound is AKB-9778, a tyrosine kinase receptor 2 (Tie2) activator, which is expected to start...
08:00 , Jan 9, 2012 |  BioCentury  |  Finance

Project management

Project management Akebia Therapeutics Inc. has decided the best way to manage its diverse clinical-stage assets is to spin out a newco - Aerpio Therapeutics Inc.Akebia will focus on anemia, while Aerpio will focus on diabetic...